Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.; Cowey, C.; Lao, C.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P.; Hill, A.; Wagstaff, J.; Carlino, M.; Haanen, J.; Maio, M.; Márquez-Rodas, I.; McArthur, G.; Ascierto, P.; Long, G.; Callahan, M.; Postow, M.; Postow, M.; Grossmann, K.; Sznol, M.; Dréno, B.; Bastholt, L.; Yang, A.; Rollin, L.; Horak, C.; Hodi, F.; Wolchok, J.; Wolchok, J.

doi:10.1056/NEJMoa1504030

Public

Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Shared by NobleBlocks on May 31, 2015 • 12:00 AM UTC

Authors:

J. Larkin

V. Chiarion-Sileni

R. Gonzalez

Abstract

Background The results of phase 1 and phase 2 studies suggest that nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab combined with ip...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!